R&D channel feed

Dai­ichi Sankyo 'dis­ap­point­ed' as FDA ex­perts spurn AML drug but vote in fa­vor of rare tu­mor drug

7 years ago

My­ovan­t's re­l­u­golix clears first uter­ine fi­broids PhI­II test, but com­pe­ti­tion from Ab­b­Vie/Neu­ro­crine makes in­vestors jit­tery

7 years ago

Re­jig­ging Mer­ck KGaA part­ner­ship, Eliot Forster gains full con­trol of the al­pha in F-star's con­stel­la­tion

7 years ago

Sol­id Bio’s high­er gene ther­a­py dose for Duchenne MD runs smack in­to a fresh set of safe­ty is­sues -- shares tum­ble

7 years ago
Cell/Gene Tx

Min­er­va claims 'pos­i­tive' PhII da­ta on de­pres­sion drug while skep­tics push stock down

7 years ago

Dai­ichi Sankyo faces FDA chal­lenges on miss­ing da­ta, cred­i­bil­i­ty and safe­ty con­cerns in hunt for 2 new drug OKs

7 years ago
Pharma

Up­dat­ed: In­ter­change­able biosim­i­lars: FDA fi­nal­izes guid­ance

7 years ago
FDA+

Biotech hits the brakes on their PhI­II piv­otal for a lead an­tibi­ot­ic as in­ves­ti­ga­tors track a high rate of kid­ney in­juries

7 years ago

Philo­gen who? A low pro­file but phar­ma-con­nect­ed Ital­ian-Swiss hy­brid steps out with $68M for a fi­nal push over the PhI­II fin­ish line

7 years ago
Financing

Sem­ma goes on a suc­cess­ful ‘fish­ing’ ex­pe­di­tion in its hunt for a di­a­betes cure

7 years ago

PhI may still be a killing field of fail­ure but PhI­II suc­cess rates have surged, sig­nal­ing tec­ton­ic shifts in bio­phar­ma R&D

7 years ago

A new­ly formed biotech launched out of George Da­ley’s Har­vard lab adds glob­al play­ers to its syn­di­cate, bring­ing its haul to $83M

7 years ago
Startups

Bay­er kicks off a $150M add-on for its cam­pus in Berke­ley

7 years ago
Cell/Gene Tx

Push­ing hard for block­buster re­turns, No­var­tis finds PhI­II da­ta to as­sert Mayzent boosts cog­ni­tive pow­ers in MS pa­tients

7 years ago

Pre­clin­i­cal da­ta on MD An­der­son Can­cer Cen­ter-de­vel­oped drug of­fers hope for Im­bru­vi­ca-re­sis­tant man­tle cell lym­phoma pa­tients

7 years ago

Once the cen­ter of a pub­lic storm of anger over de­nied drug, Chimerix now can’t even re­cruit pa­tients for their tri­als

7 years ago

An­oth­er PhI­II #fail for Bris­tol-My­ers’ star drug rais­es fresh ques­tions about their R&D strat­e­gy as Mer­ck surges fur­ther ahead

7 years ago

New study spot­lights a link be­tween block­buster SGLT2 drugs and po­ten­tial­ly lethal gan­grene

7 years ago

Look­ing to top­ple Pfiz­er's Pre­vnar 13 dy­nasty, Mer­ck claims an­oth­er win for its 'break­through' pneu­mo­coc­cal con­ju­gate vac­cine

7 years ago

Pfiz­er buys a rare dis­ease biotech for $340M-plus, putting them on a path to com­pete with Bio­Marin

7 years ago
Pharma

Gilead wa­gers $109M — cash — that this biotech can il­lu­mi­nate a drug dis­cov­ery path point­ed straight in­to the kid­ney

7 years ago

As­traZeneca’s $7B bet on Dai­ichi Sankyo’s an­ti­body drug con­ju­gate pays off with piv­otal da­ta to back their reg­u­la­to­ry pitch­es

7 years ago

Re­gen­eron’s star bis­pe­cif­ic is linked to 2 deaths in a small study — which was no help for its Q1 call

7 years ago

$250M As­traZeneca spin­off preps leap in­to 3-way bat­tle with ti­tans for a rare dis­ease mar­ket that spans the globe

7 years ago
First page Previous page 245246247248249250251 Next page Last page
A service from the Financial Times